Status: Recruiting
Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma
This study investigates the therapeutic benefit of consolidative local therapy with extirpative surgery for participants with locally advanced or oligo-metastatic urothelial carcinoma that have disease control with enfortumab vedotin-based systemic therapy and surgically resectable or previously radiated metastatic sites.
Participants needed: 32
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Yale UniversityUpdated: Jun 10, 2026Locations: 1
Eligibility criteria
Be at least 18 years of age. [+14]
Received systemic anti-cancer therapy within three weeks prior to the surgery. [+5]